

1 significance of the 7.5 percent figure at the bottom of that  
2 page?

3 A Yes. At this time we would have known that 5 percent  
4 was satisfactory in killing the microorganism. We wanted a  
5 safety margin to allow for a possible fall in concentration  
6 in storage so we selected 7.5. This would be once again a  
7 step into the unknown because we had not done that before.  
8 So the 7.5 I have written down there, rates, which refers to  
9 check the stability, having put ethanol into that  
10 concentration, the taste, which is another example of  
11 considering the patient, perhaps when we change the  
12 concentration, does it change the peppermint flavor in any  
13 way, because we had other experience with some of the other  
14 preservatives where there had been changes in tastes as a  
15 result of changing the preservatives, and also clarity.  
16 Would the elegance of this product be affected in any way?

17 We saw the product here yesterday, it's a gleaming  
18 bottle and a crystal clear fluid. We had to check that there  
19 wouldn't be any haze developing, which is a possibility,  
20 having seen on other products the cellose forming a haze when  
21 certain constituency were varied, either by concentration or  
22 the actual constituent. So 7.5, to sum up, the target we  
23 were going for, but there were some things to check for.

24 Q Doctor, based on that testimony, does that take us  
25 right through the July-October 1985 time period on what I

1 referred to previously as the '249 patent time line?

2 A Yes, that takes up that period.

3 Q The event at the end of October states Dr. Long  
4 concluded that 7.5 percent weight/volume ethanol would be  
5 included in the Zantac Syrup formulation to ensure a minimum  
6 of 5 percent weight/volume ethanol would remain in the  
7 product throughout its assigned shelf-life.

8 A Yes, it does.

9 Q At this point in time had you invented anything, in  
10 your opinion, adding the 7.5 percent ethanol to the syrup?

11 A No, because to add alcohol to a syrup is fairly  
12 ordinary mundane activity. It was well known that alcohol  
13 was contained in syrups.

14 Q At this point you had successfully killed the  
15 *Pseudomonas cepacia* problem; is that correct?

16 A I had killed that -- I had selected the ethanol, which  
17 had killed the *Pseudomonas cepacia*. So that is, that's an  
18 advance in science so it is a discovery.

19 Q That's not the subject of your invention; is that  
20 correct?

21 A No, indeed it's not.

22 Q You never claimed an invention for killing the  
23 *Pseudomonas cepacia*; is that correct?

24 A No, there is no claim for that at all.

25 Q Were you involved in stability testing of the revised



1 A The conclusion that is stated here it says the  
2 calculations formed here indicate that, one, ethanol enhances  
3 stability of ranitidine; two, PET is a better container than  
4 glass with respect to ranitidine.

5 Q And can I also direct your attention to page 84468 and  
6 can you read for the record what the conclusion is stated  
7 there?

8 A In conclusion, the weight of evidence would imply that  
9 alcohol imparts a genuine stabilizing effect with respect to  
10 ranitidine.

11 Q So, Doctor, is it correct to say that the discovery of  
12 the enhancements that occurred upon the addition of alcohol  
13 to the Zantac Syrup formulation came as a result of the  
14 stability analysis that was carried out under your direction?

15 A Yes. It was my instruction to include alcohol. I  
16 instructed the team to set up stability programs and to  
17 generate the stability data and also to analyze that data as  
18 it became available. During that analysis our main concern  
19 was to ensure that the stability of ranitidine was not  
20 adversely affected by the inclusion of ether alcohol.

21 Q I could direct your attention, Dr. Long, back to  
22 plaintiffs' trial exhibit 64 to page Y060620, and focusing in  
23 on the text, ethanol does not adversely affect the stability  
24 of ranitidine, consequently the shelf-life predicted for the  
25 formulation with ethanol should be similar to the formulas

WALLS REPORTING, INC.  
714 PARK AVENUE, BALTIMORE, MD 21201  
410-728-9020 FAX 410-728-9024

1 without ethanol.

2 Can you explain the context of that statement?

3 A Yes. In this discussion of results we were comparing  
4 the results for the concentration of ranitidine in the  
5 presence of ethanol and in its absence.

6 The data showed that the stability was not  
7 adversely affected. In fact, there was an indication, a  
8 strong indication that, if anything, it was the reverse, and  
9 it wasn't until we came to write the NDA where we had two  
10 sets of information, formulation without ethanol and  
11 formulation with, that we actually studied the results in  
12 detail to look at the effect of the alcohol. What I was  
13 looking for, what the team was looking for was no adverse  
14 stability, but we had the surprise that, in fact, the reverse  
15 had occurred and there was a strong indication that by adding  
16 the alcohol we had, in fact, enhanced the stability.

17 In the NDA we haven't claimed this but we have put  
18 in the phrase does not adversely effect, which is a  
19 qualifier, rather than to say the addition of alcohol does  
20 not effect. So rather than leave it blank, that there is no  
21 effect at all, we have said it's not adversely affecting the  
22 stability.

23 THE COURT: Is your testimony that that was a  
24 conscious decision to use the adverb?

25 THE WITNESS: It was, in that normally we would, if

WALLS REPORTING, INC.  
714 PARK AVENUE, BALTIMORE, MD 21201  
410-728-9020 FAX 410-728-9024